Diabetes franchise drives 1Q18 for Lilly

Strong sales from the diabetes franchise of Eli Lilly and Co. (NYSE:LLY) led to 1Q18 results that outpaced consensus estimates. On Tuesday, the pharma reported revenue of $5.7 billion for

Read the full 309 word article

How to gain access

Continue reading with a
two-week free trial.